CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM114387
035-os BibID:(Scopus)85169934513
Első szerző:Caporali, Roberto
Cím:Start RA Treatment - Biologics or JAK-Inhibitors? / Roberto Caporali, Sabino Germinario, Dorottya Kacsándi, Ernest Choy, Zoltán Szekanecz
Dátum:2024
ISSN:1568-9972
Megjegyzések:Janus Kinase inhibitors (JAKi) have been approved for the treatment of Rheumatoid Arthritis (RA) for several years. They are the first oral advanced treatment with efficacy similar to, if not greater than, biologic agents. Recently, concerns over their safety was raised by the results from Oral Surveillance trial suggesting that tofacitinib, one of the JAKi, was associated with higher cardiovascular adverse events and malignancies than TNF inhibitors (TNFi). Since then, regulatory authorities have added warnings to the labels of JAKi. On this purpose, whether rheumatologists should use JAKi as first line advance treatment has become a controversial topic. Some rheumatologists have argued that biologics should be first line advance treatment since there are extensive effectiveness and safety data. In addition, with the advent of biosimilar drugs, they are the most cost-effective treatment. On the other hand, JAKi are very efficacious and are generally safe apart from older and high-risk patients. When TNFi are contraindicated and in certain RA patients, especially when an oral drug is preferable, JAKi have significant advantage providing patients are involved in the decision-making process.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Autoimmunity Reviews. - 23 : 1 (2024), p.1-4. _
További szerzők:Germinario, Sabino Kacsándi Dorottya Choy, Ernest Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
http://dx.doi.org/10.1016/j.autrev.2023.103429
Borító:

2.

001-es BibID:BIBFORM056667
Első szerző:Choy, Ernest
Cím:Cardiovascular risk in rheumatoid arthritis : recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment / Ernest Choy, Kandeepan Ganeshalingam, Anne Grete Semb, Zoltán Szekanecz, Michael Nurmohamed
Dátum:2014
ISSN:1462-0324 1462-0332
Megjegyzések:Risk of cardiovascular (CV) disease is increased among RA patients. High inflammatory burden associated with RA appears to be a key driver of the increased cardiovascular risk. Inflammation is linked with accelerated atherosclerosis and associated with a paradoxical inversion of the relationship between CV risk and lipid levels in patients with untreated RA, recently coined the lipid paradox. Furthermore, the inflammatory burden is also associated with qualitative as well as quantitative changes in lipoproteins, with the anti-inflammatory and atheroprotective roles associated with high-density lipoprotein cholesterol significantly altered. RA therapies can increase lipid levels, which may reflect the normalization of lipids due to their inflammatory-dampening effects. However, these confounding influences of inflammation and RA therapies on lipid profiles pose challenges for assessing CV risk in RA patients and interpretation of traditional CV risk scores. In this review we examine the relationship between the increased inflammatory burden in RA and CV risk, exploring how inflammation influences lipid profiles, the impact of RA therapies and strategies for identifying and monitoring CV risk in RA patients aimed at improving CV outcomes.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
rheumatoid arthritis
cardiovascular disease
inflammation
atherosclerosis
dyslipidaemias
antirheumatic agents
Megjelenés:Rheumatology Oxford. - 53 : 12 (2014), p. 2143-2154. -
További szerzők:Ganeshalingam, Kandeepan Semb, Anne Grete Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Nurmohamed, Michael T.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

3.

001-es BibID:BIBFORM096109
035-os BibID:(WOS)000723328800001 (Scopus)85122302204
Első szerző:Nagy György
Cím:EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis / Nagy György, Roodenrijs Nadia M. T., Welsing Paco M. J., Kedves Melinda, Hamar Attila, van der Goes Marlies C., Kent Alison, Bakkers Margot, Pchelnikova Polina, Blaas Etienne, Senolt Ladislav, Szekanecz Zoltan, Choy Ernest H., Dougados Maxime, Jacobs Johannes W. G., Geenen Rinie, Bijlsma Johannes W. J., Zink Angela, Aletaha Daniel, Schoneveld Leonard, van Riel Piet, Dumas Sophie, Prior Yeliz, Nikiphorou Elena, Ferraccioli Gianfranco, Schett Georg, Hyrich Kimme L., Mueller-Ladner Ulf, Buch Maya H., McInnes Iain B., van der Heijde Désirée, van Laar Jacob M.
Dátum:2022
ISSN:0003-4967
Megjegyzések:Objective To develop evidence-based European Alliance of Associations for Rheumatology (EULAR) points to consider (PtCs) for the management of difficultto-treat rheumatoid arthritis (D2T RA). Methods An EULAR Task Force was established comprising 34 individuals: 26 rheumatologists, patient partners and rheumatology experienced health professionals. Two systematic literature reviews addressed clinical questions around diagnostic challenges, and pharmacological and nonpharmacological therapeutic strategies in D2T RA. PtCs were formulated based on the identified evidence and expert opinion. Strength of recommendations (SoR, scale A?D: A typically consistent level 1 studies and D level 5 evidence or inconsistent studies) and level of agreement (LoA, scale 0?10: 0 completely disagree and 10 completely agree) of the PtCs were determined by the Task Force members. Results Two overarching principles and 11 PtCs were defined concerning diagnostic confirmation of RA, evaluation of inflammatory disease activity, pharmacological and non-pharmacological interventions, treatment adherence, functional disability, pain, fatigue, goal setting and self-efficacy and the impact of comorbidities. The SoR varied from level C to level D. The mean LoA with the overarching principles and PtCs was generally high (8.4?9.6). Conclusions These PtCs for D2T RA can serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies. High-quality evidence was scarce. A research agenda was created to guide future research.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
arthritis
fibromyalgia
inflammation
rheumatoid
ultrasonography
Megjelenés:Annals Of The Rheumatic Diseases. - 81 : 1 (2022), p. 20-33. -
További szerzők:Roodenrijs, Nadia M. T. Welsing, Paco M. J. Kedves Melinda Hamar Attila Béla (1990-) (általános orvos) van der Goes, Marlies C. Kent, Alison Bakkers, Margôt Pchelnikova, Polina Blaas, Etienne Senolt, Ladislav Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Choy, Ernest Dougados, Maxime Jacobs, Johannes W. G. Geenen, Rinie Bijlsma, Johannes W. Zink, Angela Aletaha, Daniel Schoneveld, Leonard van Riel, Piet Dumas, Sophie Prior, Yeliz Nikiphorou, Elena (reumatológus) Ferraccioli, Gianfranco Schett, Georg Hyrich, Kimme L. Mueller-Ladner, Ulf Buch, Maya H. McInnes, Iain B. van der Heijde, Désirée van Laar, Jacob M.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM088182
035-os BibID:(WOS)000607296800019 (Scopus)85098069546
Első szerző:Nagy György
Cím:EULAR definition of difficult-to-treat rheumatoid arthritis / György Nagy, Nadia M. T. Roodenrijs, Paco M. J. Welsing, Melinda Kedves, Attila Hamar, Marlies C. van der Goes, Alison Kent, Margot Bakkers, Etienne Blaas, Ladislav Senolt, Zoltan Szekanecz, Ernest Choy, Maxime Dougados, Johannes W. G. Jacobs, Rinie Geenen, Hans W. J. Bijlsma, Angela Zink, Daniel Aletaha, Leonard Schoneveld, Piet van Riel, Loriane Gutermann, Yeliz Prior, Elena Nikiphorou, Gianfranco Ferraccioli, Georg Schett, Kimme L. Hyrich, Ulf Mueller-Ladner, Maya H. Buch, Iain B. McInnes, Désirée van der Heijde, Jacob M. van Laar
Dátum:2021
ISSN:0003-4967
Megjegyzések:Background Despite treatment according to the current management recommendations, a significant proportion of patients with rheumatoid arthritis (RA) remain symptomatic. These patients can be considered to have 'difficult-to-treat RA'. However, uniform terminology and an appropriate definition are lacking. Objective The Task Force in charge of the "Development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis" aims to create recommendations for this underserved patient group. Herein, we present the definition of difficult-to-treat RA, as the first step. Methods The Steering Committee drafted a definition with suggested terminology based on an international survey among rheumatologists. This was discussed and amended by the Task Force, including rheumatologists, nurses, health professionals and patients, at a face-to-face meeting until sufficient agreement was reached (assessed through voting). Results The following three criteria were agreed by all Task Force members as mandatory elements of the definition of difficult-to-treat RA: (1) Treatment according to European League Against Rheumatism (EULAR) recommendation and failure of ?2 biological disease-modifying antirheumatic drugs (DMARDs)/targeted synthetic DMARDs (with different mechanisms of action) after failing conventional synthetic DMARD therapy (unless contraindicated); (2) presence of at least one of the following: at least moderate disease activity; signs and/or symptoms suggestive of active disease; inability to taper glucocorticoid treatment; rapid radiographic progression; RA symptoms that are causing a reduction in quality of life; and (3) the management of signs and/or symptoms is perceived as problematic by the rheumatologist and/or the patient. Conclusions The proposed EULAR definition for difficult-to-treat RA can be used in clinical practice, clinical trials and can form a basis for future research.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 80 : 1 (2021), p. 31-35. -
További szerzők:Roodenrijs, Nadia M. T. Welsing, Paco M. J. Kedves Melinda Hamar Attila Béla (1990-) (általános orvos) Goes, Marlies C. van der Kent, Alison Bakkers, Margôt Blaas, Etienne Senolt, Ladislav Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Choy, Ernest Dougados, Maxime Jacobs, Johannes W. G. Geenen, Rinie Bijlsma, Johannes W. Zink, Angela Aletaha, Daniel Schoneveld, Leonard Riel, Piet van Gutermann, Loriane Prior, Yeliz Nikiphorou, Elena (reumatológus) Ferraccioli, Gianfranco Schett, Georg Hyrich, Kimme L. Mueller-Ladner, Ulf Buch, Maya H. McInnes, Iain B. Heijde, Désirée van der Laar, Jacob M. van
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM114359
035-os BibID:(WoS)001065800700001 (Scopus)85179996474
Első szerző:Taylor, Peter C.
Cím:Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases / Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltan Szekanecz, Ricardo M. Xavier, John D. Isaacs, Sander Strengholt, Julie M. Parmentier, Ralph Lippe, Yoshiya Tanaka
Dátum:2024
ISSN:1462-0324 1462-0332
Megjegyzések:Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as RA, psoriasis, atopic dermatitis and IBD. Several small-molecule JAK inhibitors (JAKis) are now approved for the treatment of various immune-mediated inflammatory diseases. There are, however, key differences between these agents that could potentially translate into unique clinical profiles. Each JAKi has a unique chemical structure, resulting in a distinctive mode of binding within the catalytic cleft of the target JAK, and giving rise to distinct pharmacological characteristics. In addition, the available agents have differing selectivity for JAK isoforms, as well as off-target effects against non-JAKs. Other differences include effects on haematological parameters, DNA damage repair, reproductive toxicity and metabolism/elimination. Here we review the pharmacological profiles of the JAKis abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib and upadacitinib.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Rheumatology. - 63 : 2 (2024), p. 298-308. -
További szerzők:Choy, Ernest Baraliakos, Xenofon Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Xavier, Ricardo M. Isaacs, John D. Strengholt, Sander Parmentier, Julie M. Lippe, Ralph Tanaka, Yoshiya
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.